Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

NCT04081389 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Anatomic Stage 0 Breast Cancer AJCC v8
Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage IA Breast Cancer AJCC v8
Anatomic Stage IB Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage IIA Breast Cancer AJCC v8
Anatomic Stage IIB Breast Cancer AJCC v8
Early-Stage Breast Carcinoma
Estrogen Receptor Negative
HER2/Neu Negative
Progesterone Receptor Negative
Prognostic Stage 0 Breast Cancer AJCC v8
Prognostic Stage I Breast Cancer AJCC v8
Prognostic Stage IA Breast Cancer AJCC v8
Prognostic Stage IB Breast Cancer AJCC v8
Prognostic Stage II Breast Cancer AJCC v8
Prognostic Stage IIA Breast Cancer AJCC v8
Prognostic Stage IIB Breast Cancer AJCC v8
Triple-Negative Breast Carcinoma

Interventions

DRUG: Celecoxib
DRUG: Cyclophosphamide
DRUG: Doxorubicin
DRUG: Doxorubicin Hydrochloride
DRUG: Paclitaxel
BIOLOGICAL: Recombinant Interferon Alfa-2b
DRUG: Rintatolimod

Sponsor

Roswell Park Cancer Institute

Collaborators

[object Object]